All In Biotech

Drug Trial Radar · NCT05841563

Clinical Trial of PM54 in Advanced Solid Tumors Patients.

Phase I/Ib, Open-label, Dose-escalating, Clinical and Pharmacokinetic Study of PM54 Administered Intravenously to Patients With Selected Advanced Solid Tumors.

Last checked: Nov 19, 2026Latest source record: Sep 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

125

Planned (sponsor's estimate)

Start

Apr 28, 2023

Primary completion

Dec 30, 2026

Study completion Apr 30, 2027

Sponsor

Lead sponsor
PharmaMarIndustry
Sponsor type
Industry
First posted
May 3, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The first part of the study (phase Ia - dose escalation) will evaluate the safety and tolerability and identify the dose-limiting toxicities (DLTs) of PM54. The second part of the study (phase Ib - safety run-in and expansion) will be to reassess the maximum tolerated dose (MTD) defined in the Phase Ia stage in a framework of more extensive premedication, and to evaluate the antitumor activity of PM54 according to the RECIST v.1.1 (or mRECIST v.1.1 in case of MPM) and/or serum markers as appropriate, in patients with selected advanced solid tumors.

Conditions

  • Advanced Solid Tumor

Interventions

  • PM54Drug

    PM54 powder for concentrate for solution for infusion (3 mg/vial) is a sterile, preservative-free, lyophilized white to yellowish cake in a single-dose vial for reconstitution prior to intravenous infusion. Each vial contains 3 mg PM54. Route of administration: Intravenous infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1a (dose escalation) and Phase1b (safety run-in): Dose-limiting toxicities (DLTs)Time frame: Day 1 Cycle 1 up to end of first cycle of treatment (Cycle 1 is 21 days)
  2. Phase 1a (dose escalation) and Phase1b (safety run-in): Treatment-emergent Adverse Events (TEAEs)Time frame: Day 1 Cycle 1 up to end of first cycle of treatment (Cycle 1 is 21 days)
  3. Phase 1a (dose escalation) and Phase1b (safety run-in): Drug-related Adverse Events (AEs)Time frame: Day 1 Cycle 1 up to end of first cycle of treatment (Cycle 1 is 21 days)
  4. Phase 1a (dose escalation) and Phase1b (safety run-in): Drug-related deathsTime frame: Day 1 Cycle 1 up to end of first cycle of treatment (Cycle 1 is 21 days)
  5. Phase 1a (dose escalation) and Phase1b (safety run-in): Serious adverse events (SAEs)Time frame: Screening up to end of first cycle of treatment (Cycle 1 is 21 days)
  6. Phase 1a (dose escalation) and Phase1b (safety run-in): Drug-related delaysTime frame: Day 1 Cycle 1 up to end of first cycle of treatment (Cycle 1 is 21 days)
  7. Phase 1a (dose escalation) and Phase1b (safety run-in): Dose reductionsTime frame: Day 1 Cycle 1 up to end of first cycle of treatment (Cycle 1 is 21 days)
  8. Phase 1a (dose escalation) and Phase1b (safety run-in): Treatment discontinuationsTime frame: Day 1 Cycle 1 up to end of first cycle of treatment (Cycle 1 is 21 days)
  9. Phase 1a (dose escalation) and Phase1b (safety run-in): Maximum tolerated dose (MTD)Time frame: Day 1 Cycle 1 up to end of first cycle of treatment (Cycle 1 is 21 days)
  10. Phase 1a (dose escalation) and Phase1b (safety run-in): Recommended dose (RD)Time frame: Day 1 Cycle 1 up to end of first cycle of treatment (Cycle 1 is 21 days)
  11. Phase1b (safety run-in): Determination of RD with more extensive premedicationTime frame: Day 1 Cycle 1 up to end of first cycle of treatment (Cycle 1 is 21 days)
  12. Phase 1b (expansion): Antitumor activityTime frame: Every 6 weeks (± 1 week) in all patients with evaluable disease until Cycle 6. For patients continuing treatment after Cycle 6, assessments performed every 9 weeks (± 1 week) while on treatment, unless otherwise indicated (Up to 48 months)

Locations

3 sites in 3 countries. Site status is shown where the registry gives one.

  • South Texas Accelerated Research Therapeutics

    San Antonio, Texas · Recruiting

  • Institut Jules Bordet

    Anderlecht, Belgium · Recruiting

  • HM Universitario Sanchinarro

    Madrid, M, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.